Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emile Ferrari

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
American Heart Journal|November 5, 2025
Evolocumab before percutaneous coronary intervention for acute myocardial infarction: Design of the AMUNDSEN trialGilles Montalescot, Leonardo Bolognese, Stanislaw Bartus, et al.
European Heart Journal|August 30, 2025
Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trialJean-Guillaume Dillinger, Théo Pezel, Laure Batias, et al.
American Heart Journal|April 23, 2025
Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: Rationale and design of the randomized ANDAMAN trialJean-Guillaume Dillinger, Théo Pezel, Laure Batias, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|May 25, 2022
Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analysesIsabelle Durand-Zaleski, Gregory Ducrocq, Maroua Mimouni, et al.
Hypertension (Dallas, Tex. : 1979)|January 25, 2017
Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension)Philippe Gosse, Antoine Cremer, Helena Pereira, et al.
Journal of the American Heart Association|October 12, 2017
Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) TrialPierre-Yves Courand, Helena Pereira, Costantino Del Giudice, et al.
European Heart Journal|May 22, 2025
Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trialNiki Procopi, Michel Zeitouni, Mathieu Kerneis, et al.
Journal of the American College of Cardiology|March 25, 2017
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary EmbolismStavros V Konstantinides, Eric Vicaut, Thierry Danays, et al.
Archives of Cardiovascular Diseases|April 9, 2024
Cardiogenic shock and chronic kidney disease: Dangerous liaisonsMiloud Cherbi, Eric Bonnefoy, Etienne Puymirat, et al.
Circulation|September 1, 2016
Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) TrialMichel Azizi, Helena Pereira, Idir Hamdidouche, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
American Heart Journal|November 5, 2025
Evolocumab before percutaneous coronary intervention for acute myocardial infarction: Design of the AMUNDSEN trialGilles Montalescot, Leonardo Bolognese, Stanislaw Bartus, et al.
European Heart Journal|August 30, 2025
Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trialJean-Guillaume Dillinger, Théo Pezel, Laure Batias, et al.
American Heart Journal|April 23, 2025
Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: Rationale and design of the randomized ANDAMAN trialJean-Guillaume Dillinger, Théo Pezel, Laure Batias, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|May 25, 2022
Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analysesIsabelle Durand-Zaleski, Gregory Ducrocq, Maroua Mimouni, et al.
Hypertension (Dallas, Tex. : 1979)|January 25, 2017
Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension)Philippe Gosse, Antoine Cremer, Helena Pereira, et al.
Journal of the American Heart Association|October 12, 2017
Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) TrialPierre-Yves Courand, Helena Pereira, Costantino Del Giudice, et al.
European Heart Journal|May 22, 2025
Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trialNiki Procopi, Michel Zeitouni, Mathieu Kerneis, et al.
Journal of the American College of Cardiology|March 25, 2017
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary EmbolismStavros V Konstantinides, Eric Vicaut, Thierry Danays, et al.
Archives of Cardiovascular Diseases|April 9, 2024
Cardiogenic shock and chronic kidney disease: Dangerous liaisonsMiloud Cherbi, Eric Bonnefoy, Etienne Puymirat, et al.
Circulation|September 1, 2016
Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) TrialMichel Azizi, Helena Pereira, Idir Hamdidouche, et al.
Pageof 11